NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
MIAMI, May 08, 2017 -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017, after the close of the U.S. financial markets on Tuesday, May 9, 2017.
OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 9, 2017.
Conference Call & Webcast Information
WHEN: Tuesday, May 9, 2017, 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 17226044
WEBCAST: http://investor.opko.com/events.cfm
For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.
Contacts: OPKO Health, Inc. David Malina, 305-575-4137 Investor Relations [email protected] Or BioReference Tara MacCay, 305-5754195 [email protected] Media Rooney & Partners Terry Rooney, 212-223-0689 [email protected] Or Marion Janic, 212-223-4017 [email protected] Investors LHA Anne Marie Fields, 212-838-3777 [email protected] Or Bruce Voss, 310-691-7100 [email protected]
